西罗莫司
他克莫司
肝细胞癌
转基因
转基因小鼠
PI3K/AKT/mTOR通路
肝癌
医学
雷帕霉素的作用靶点
癌症
内科学
癌症研究
药理学
生物
移植
信号转导
生物化学
基因
作者
Hyung Soon Lee,Joon Ye Kim,Simon Weonsang Ro,Myoung Soo Kim,Haeryoung Kim,Dong Jin Joo
出处
期刊:Yonsei Medical Journal
[Yonsei University College of Medicine]
日期:2022-01-01
卷期号:63 (11): 1007-1007
被引量:1
标识
DOI:10.3349/ymj.2022.0247
摘要
We investigate whether low-dose rapamycin is effective in preventing hepatocellular carcinoma (HCC) growth and treating HCC after tumor development in transgenic mice.We established transgenic mice with HCC induced by activated HrasG12V and p53 suppression. Transgenic mice were randomly assigned to five experimental groups: negative control, positive control, tacrolimus only, rapamycin only, and tacrolimus plus rapamycin. The mice were further divided into two groups according to time to commencement of immunosuppressant treatment: de novo treatment and post-tumor development.In the de novo treatment group, marked suppression of tumor growth was observed in the rapamycin only group. In the post-tumor development group, the rapamycin only group displayed no significant suppression of tumor growth, compared to the positive control group. In T lymphocyte subset analysis, the numbers of CD4+ effector T cells and CD4+ regulatory T cells were significantly lower in the positive control, tacrolimus only, and tacrolimus plus rapamycin groups than the negative control group. Immunohistochemical analysis revealed significantly higher expression of phosphorylated-mTOR, 4E-BP1, and S6K1 in the positive control group than in the rapamycin only group.Low-dose rapamycin might be effective to prevent HCC growth, but may be ineffective as a treatment option after HCC development.
科研通智能强力驱动
Strongly Powered by AbleSci AI